{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-025866","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.350739+00:00","generated_at":"2026-06-05T03:22:20.183440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5","bullets":["Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.","Cash at Dec 31, 2023 was $8.6M, down from $18.1M; runway forecast into 2H 2025.","Enrolled 5th of 7 dosing cohorts in ReSPECT-LM Phase 1 trial for leptomeningeal metastases; orphan drug designation granted for breast cancer LM.","Received $3.3M advance from CPRIT grant ($17.6M total); total grant revenue recognized $4.9M in 2023.","Plans FDA meetings in 2024 to align on pivotal trial design for LM and GBM; registrational trial target 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-025866","json":"https://secwatch.observer/filing/0000950170-24-025866.json","markdown":"https://secwatch.observer/filing/0000950170-24-025866.md","text":"https://secwatch.observer/filing/0000950170-24-025866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/0000950170-24-025866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/pstv-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:22:20.183440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab9b8b0f6a59c50c27dc4356f726c2fec7c3120c","claim":"PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income $(13.3) million, or $(4.24) per share, EPS $(4.24) per share.","evidence_excerpt":"Plus Therapeutics, Inc. (the “Company”) reported financial results for the fourth quarter and year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/0000950170-24-025866-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"$(13.3) million, or $(4.24) per share"},{"label":"EPS","value":"$(4.24) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}